Relay Therapeutics Inc
RLAY8.920USD
+0.770+9.45%
終値 02/06, 16:00（ET）15分遅れの株価
1.54B時価総額
損失額直近12ヶ月PER
詳細情報 Relay Therapeutics Inc 企業名
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Relay Therapeutics Incの企業情報
企業コードRLAY
会社名Relay Therapeutics Inc
上場日Jul 16, 2020
最高経営責任者「CEO」Patel (Sanjiv K)
従業員数261
証券種類Ordinary Share
決算期末Jul 16
本社所在地60 Hampshire Street
都市CAMBRIDGE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02139
電話番号16173708837
ウェブサイトhttps://relaytx.com/
企業コードRLAY
上場日Jul 16, 2020
最高経営責任者「CEO」Patel (Sanjiv K)
Relay Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-19913.00%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
120.71K
-13038.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexis A. Borisy
Mr. Alexis A. Borisy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-19913.00%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
120.71K
-13038.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
収益内訳
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
United States
0.00
0.00%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Tue, Nov 18
更新時刻: Tue, Nov 18
株主統計
種類
株主統計
株主統計
比率
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
他の
52.98%
株主統計
株主統計
比率
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
他の
52.98%
種類
株主統計
比率
Hedge Fund
36.60%
Investment Advisor
27.59%
Private Equity
16.70%
Investment Advisor/Hedge Fund
12.95%
Research Firm
2.08%
Individual Investor
1.27%
Venture Capital
0.91%
Sovereign Wealth Fund
0.48%
Family Office
0.38%
他の
1.05%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
457
170.34M
98.28%
-42.79M
2025Q3
457
168.31M
97.11%
-38.09M
2025Q2
460
180.78M
105.44%
-7.40M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
SB Investment Advisers (UK) Limited
27.90M
16.1%
--
--
Sep 30, 2025
Commodore Capital LP
17.00M
9.81%
+3.65M
+27.34%
Sep 30, 2025
Point72 Asset Management, L.P.
14.77M
8.52%
+1.33M
+9.88%
Sep 30, 2025
Casdin Capital, LLC
11.34M
6.54%
-57.19K
-0.50%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
10.48M
6.05%
-143.98K
-1.35%
Sep 30, 2025
The Vanguard Group, Inc.
9.37M
5.4%
+15.89K
+0.17%
Sep 30, 2025
Bellevue Asset Management AG
8.35M
4.82%
+114.74K
+1.39%
Sep 30, 2025
Tang Capital Management, LLC
8.07M
4.65%
--
--
Sep 30, 2025
State Street Investment Management (US)
5.07M
2.92%
-136.80K
-2.63%
Sep 30, 2025
Nextech Invest, Ltd.
3.85M
2.22%
--
--
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
1.4%
Tema Oncology ETF
0.98%
ALPS Medical Breakthroughs ETF
0.51%
State Street SPDR S&P Biotech ETF
0.33%
ProShares Ultra Nasdaq Biotechnology
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
Avantis US Small Cap Equity ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
iShares Biotechnology ETF
0.08%
詳細を見る
Virtus LifeSci Biotech Clinical Trials ETF
比率1.4%
Tema Oncology ETF
比率0.98%
ALPS Medical Breakthroughs ETF
比率0.51%
State Street SPDR S&P Biotech ETF
比率0.33%
ProShares Ultra Nasdaq Biotechnology
比率0.17%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.16%
Avantis US Small Cap Equity ETF
比率0.14%
Invesco Nasdaq Biotechnology ETF
比率0.12%
Invesco RAFI US 1500 Small-Mid ETF
比率0.09%
iShares Biotechnology ETF
比率0.08%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
